WILMINGTON, Mass.--(BUSINESS WIRE)--Sirtex, a leading developer of targeted and innovative cancer therapies, provided an unrestricted grant to convene the Radioembolization Brachytherapy Oncology Consortium (REBOC). The goal of the consortium was to standardize the indications, techniques and dosimetry used for Yittrium-90 (Y90) microspheres hepatic brachytherapy. The recommendations are published in the May issue of the International Journal of Radiation Oncology Biology Physics. Sirtex manufactures SIR-Spheres® microspheres, the only FDA-approved microsphere therapy for advanced colorectal cancer that has spread to the liver.1